Liquid Biopsy in Pediatric Renal Cancer: Stage I and Stage IV Cases Compared

Elisabetta Rossi, Angelica Zin, Antonella Facchinetti, Cristina Poggiana, Lucia Tombolan, Maria Carmen Affinita, Paolo Bonvini, Luisa Santoro, Francesca Schiavi, Gianni Bisogno, Rita Zamarchi

Research output: Contribution to journalArticlepeer-review


Pediatric renal cancer is rare, and robust evidence for treatment recommendations is lacking. In the perspective of personalized medicine, clinicians need new biomarkers to improve risk stratification and patients' follow-up. Herein, we analyzed some liquid biopsy tools, which have been never tested in pediatric renal cancer: namely, circulating tumor cells (CTCs); the expression of M30, an apoptosis marker, to test CTC metastatic potential; and c-MET expression in CTCs, because of its role in renal cancer progression and drug-resistance. Furthermore, we evaluated the Circulating Endothelial Cells (CECs), whose utility we previously demonstrated in adult metastatic renal cancer treated with anti-angiogenic therapy. We compared two renal cell carcinomas of clear-cell type, stage I and IV, which underwent surgery and surgery plus Sunitinib, respectively. Baseline CTC level and its changes during follow-up were consistent with patients' outcome. In case 2, stage IV, the analysis of CECs performed during Sunitinib revealed a late response to treatment consistent with poor outcome, as the finding of M30-negative, viable cells. Noteworthily, few CTCs were MET-positive in both cases. Our study highlights the feasibility for a change in the prognostic approach and follow-up of childhood renal cancer, with a view to guide a better treatment design.

Original languageEnglish
Article number810
Pages (from-to)1-7
Number of pages7
Issue number10
Publication statusPublished - Oct 12 2020


Dive into the research topics of 'Liquid Biopsy in Pediatric Renal Cancer: Stage I and Stage IV Cases Compared'. Together they form a unique fingerprint.

Cite this